Trials Sponsors Conditions Drugs Pricing

Conditions

Pulmonary Aspergillosis Invasive Ventilator Associated Pneumonia

Keywords

Pulmonary invasive aspergillosisventilator-associated-pneumoniamechanical ventilationnosocomial infections

Outcome Measures

Primary Outcomes (1)

Incidence of probable or proven IPA according to the Verweij criteria in patients with suspected VAP
On the 1 day of inclusion

Secondary Outcomes (6)

Incidence of IPA according to the Blot criteria
On the 1 day of inclusion
Incidence of Aspergillus tracheobronchitis associated with IPA according to the Verweij criteria
On the 1 day of inclusion
Incidence of IPA according to the Verweij criteria in the subgroup without risk factors.
On the 1 day of inclusion
Mortality
at 28 days
Length of stay in intensive care unit
Until discharge from the ICU, an average 28 days
+1 more secondary outcomes

Study Arms (1)

Patients with suspected ventilator-associated pneumonia

Other: Biological examinations performed on blood and BAL

Interventions

Biological examinations performed on blood and BALOther

Direct examination and culture of BAL Galactomannan in serum and BAL Serum 1,3 beta D glucans Aspergillus PCR in BAL

Patients with suspected ventilator-associated pneumonia

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients hospitalized in ICU

You may qualify if:

Adult patient (age ≥ 18 years),

Sponsors & Collaborators

University Hospital, Lille
Otherlead
Pfizer
Industrycollaborator

Study Sites (1)

Pôle de Réanimation Hôpital R. Salengro, CHU de Lille

Lille, France

MeSH Terms

Conditions

Pneumonia, Ventilator-AssociatedInvasive Pulmonary AspergillosisCross Infection

Condition Hierarchy (Ancestors)

Healthcare-Associated PneumoniaInfectionsPneumoniaRespiratory Tract InfectionsLung DiseasesRespiratory Tract DiseasesIatrogenic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsPulmonary AspergillosisAspergillosis

Study Officials

Saad NSEIR, MD,PhD
University Hospital, Lille
PRINCIPAL INVESTIGATOR

Enrollment

263 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 15, 2022

First Posted

January 4, 2023

Study Start

August 28, 2023

Actual (reported)

Incidence of Invasive Pulmonary Aspergillosis in Ventilator-associated Pneumonia

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (6)

Study Arms (1)

Patients with suspected ventilator-associated pneumonia

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (6)

Study Arms (1)

Patients with suspected ventilator-associated pneumonia

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations